Tests radiotherapy with immunotherapy for locally advanced lung cancer

Trial details

Who runs it

Sun Yat-sen University

Trial code

NCT07874464

Record updated

14 October 2026

Original description

This is a prospective, randomized phase II study evaluating concurrent chemoradiotherapy combined with full-course immunotherapy or consolidative immunotherapy in patients with unresectable, locally advanced non-small cell lung cancer.Read full original descriptionShow less

A Prospective Phase II Study to Evaluate Concurrent Radiotherapy Combined With Full-course Immunotherapy or Concurrent Radiotherapy Combined With Consolidation Immunotherapy for Locally Advanced Non-small Cell Lung Cancer

This is a prospective, randomized phase II study evaluating concurrent chemoradiotherapy combined with full-course immunotherapy or consolidative immunotherapy in patients with unresectable, locally advanced non-small cell lung cancer.

Inclusion: Male or female patients aged 18-75 years ; Histologically or cytologically confirmed, locally advanced, unresectable stage III non-small cell lung cancer (NSCLC); Wild-type EGFR, ALK, and ROS1; No prior chemotherapy, radiotherapy, surgery, targeted therapy, or immunotherapy; Availability of unstained archival tumor tissue samples sufficient for analysis; Life expectancy of ≥12 weeks; World Health Organization (WHO) performance status of 0 or 1; Female patients must not be breastfeeding; Adequate organ and bone marrow function, meeting all of the following criteria: Forced expiratory volume in 1 second (FEV1) ≥800 mL; Absolute neutrophil count ≥1.5 × 10⁹/L; Platelet count ≥100 × 10⁹/L; Hemoglobin ≥9.0 g/dL; Creatinine clearance ≥50 mL/min, calculated using the Cockcroft-Gault formula (Cockcroft and Gault, 1976); Serum bilirubin ≤1.5 times the upper limit of normal (ULN); Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 times ULN.

Exclusion: Patients meeting any of the following criteria will not receive induction therapy:; Concurrent participation in another clinical study, unless it is an observational, non-interventional study; Prior treatment with any anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibody; Major surgery within 4 weeks before study entry, excluding procedures for vascular access; Patients meeting any of the following criteria will not proceed to concurrent chemoradiotherapy:; Patients meeting any of the following criteria will not proceed to consolidation immunotherapy:; Disease progression during concurrent chemoradiotherapy; Use of immunosuppressive medication within 28 days before the first dose of dual immunotherapy, except for intranasal or inhaled corticosteroids at physiological doses, or systemic corticosteroids at doses not exceeding 10 mg/day of prednisone or equivalent. Corticosteroids used to manage chemoradiotherapy-related toxicity are permitted; Unresolved toxicity of CTCAE grade >2 from prior chemoradiotherapy; Grade ≥2 pneumonitis resulting from prior chemoradiotherapy; Any previous grade ≥3 immune-related adverse event (irAE), or any unresolved irAE of grade >1; Mixed small cell and non-small cell lung cancer histology; Active autoimmune disease or a history of autoimmune disease within the past 2 years; Active inflammatory bowel disease or a history of inflammatory bowel disease, such as Crohn's disease or ulcerative colitis; History of primary immunodeficiency; History of organ transplantation requiring immunosuppressive therapy; Uncontrolled intercurrent illness, including but not limited to ongoing or active infection, symptomatic congestive heart failure, poorly controlled hypertension, unstable angina, cardiac arrhythmia, active peptic ulcer disease or gastritis, or active bleeding disorders; known hepatitis B surface antigen (HBsAg) positivity with HBV DNA >500 IU/mL, hepatitis C, or human immunodeficiency virus (HIV) infection; or psychiatric illness or social circumstances that would limit compliance with study requirements or impair the ability to provide written informed consent; Known history of tuberculosis, except for old, inactive pulmonary tuberculosis; History of another primary malignancy within the past 5 years, except adequately treated basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix; Locoregional disease progression that, in the judgment of the radiation oncologist, precludes definitive chemoradiotherapy because normal tissue dose constraints cannot be met; Any of the following organ or bone marrow impairments: FEV1 <800 mL; Absolute neutrophil count <1.5 × 10⁹/L; Platelet count <100 × 10⁹/L; Hemoglobin <9.0 g/dL; Creatinine clearance <50 mL/min, calculated using the Cockcroft-Gault formula (Cockcroft and Gault, 1976); Serum bilirubin >1.5 times ULN; AST and ALT >2.5 times ULN; Pregnancy or breastfeeding; or male or female patients of reproductive potential who are not using effective contraception; Development of distant metastases; WHO performance status of 2-4.

ClinicalTrials.gov NCT07874464